AU2007329808B2 - 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulators - Google Patents

1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulators Download PDF

Info

Publication number
AU2007329808B2
AU2007329808B2 AU2007329808A AU2007329808A AU2007329808B2 AU 2007329808 B2 AU2007329808 B2 AU 2007329808B2 AU 2007329808 A AU2007329808 A AU 2007329808A AU 2007329808 A AU2007329808 A AU 2007329808A AU 2007329808 B2 AU2007329808 B2 AU 2007329808B2
Authority
AU
Australia
Prior art keywords
phenyl
compound
yield
trifluoromethoxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007329808A
Other languages
English (en)
Other versions
AU2007329808A1 (en
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2007329808A1 publication Critical patent/AU2007329808A1/en
Application granted granted Critical
Publication of AU2007329808B2 publication Critical patent/AU2007329808B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007329808A 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulators Ceased AU2007329808B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
US60/862,540 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators

Publications (2)

Publication Number Publication Date
AU2007329808A1 AU2007329808A1 (en) 2008-06-12
AU2007329808B2 true AU2007329808B2 (en) 2013-11-07

Family

ID=39386481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007329808A Ceased AU2007329808B2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulators

Country Status (23)

Country Link
US (2) US8168659B2 (enExample)
EP (2) EP2099784B1 (enExample)
JP (2) JP5331002B2 (enExample)
KR (2) KR101088229B1 (enExample)
CN (2) CN101528733B (enExample)
AR (1) AR063497A1 (enExample)
AT (1) ATE492543T1 (enExample)
AU (1) AU2007329808B2 (enExample)
BR (1) BRPI0717347A2 (enExample)
CA (2) CA2667372C (enExample)
CL (1) CL2007003002A1 (enExample)
CY (1) CY1111140T1 (enExample)
DE (1) DE602007011495D1 (enExample)
DK (2) DK2099784T3 (enExample)
EA (2) EA015175B1 (enExample)
ES (2) ES2398388T3 (enExample)
MX (2) MX2009004053A (enExample)
PE (1) PE20080926A1 (enExample)
PL (2) PL2094684T3 (enExample)
PT (2) PT2099784E (enExample)
SI (2) SI2094684T1 (enExample)
TW (1) TW200825067A (enExample)
WO (2) WO2008070306A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
BRPI0910775A2 (pt) 2008-04-22 2015-09-29 Lilly Co Eli compostos 1,5-difenil pirrolidin-2-ona como ligantes cb-1
US8426448B2 (en) 2008-04-22 2013-04-23 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
AU2005214084B2 (en) * 2004-02-19 2010-06-03 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
EA015175B1 (ru) 2011-06-30
PL2099784T3 (pl) 2013-05-31
PE20080926A1 (es) 2008-07-19
ES2356025T3 (es) 2011-04-04
EA015745B1 (ru) 2011-10-31
SI2099784T1 (sl) 2013-02-28
CY1111140T1 (el) 2015-06-11
SI2094684T1 (sl) 2011-04-29
MX2009004054A (es) 2009-04-27
EP2094684B1 (en) 2010-12-22
JP5331002B2 (ja) 2013-10-30
EA200970405A1 (ru) 2009-12-30
CA2667372A1 (en) 2008-06-12
AU2007329808A1 (en) 2008-06-12
WO2008070306A3 (en) 2008-07-31
CN101528733A (zh) 2009-09-09
CN101528733B (zh) 2013-10-16
DK2094684T3 (da) 2011-03-14
CN101528732B (zh) 2013-04-03
KR101088236B1 (ko) 2011-11-30
BRPI0717347A2 (pt) 2014-01-14
JP5331001B2 (ja) 2013-10-30
CN101528732A (zh) 2009-09-09
US20090275618A1 (en) 2009-11-05
CA2667210C (en) 2013-09-24
ES2398388T3 (es) 2013-03-15
EP2099784B1 (en) 2012-12-12
KR20090071613A (ko) 2009-07-01
DK2099784T3 (da) 2013-01-14
JP2010507589A (ja) 2010-03-11
PL2094684T3 (pl) 2011-05-31
EP2094684A2 (en) 2009-09-02
MX2009004053A (es) 2009-04-27
WO2008070305A2 (en) 2008-06-12
ATE492543T1 (de) 2011-01-15
EA200970404A1 (ru) 2009-10-30
CA2667210A1 (en) 2008-06-12
US20100016375A1 (en) 2010-01-21
EP2099784A2 (en) 2009-09-16
DE602007011495D1 (de) 2011-02-03
KR101088229B1 (ko) 2011-11-30
PT2094684E (pt) 2011-01-28
AR063497A1 (es) 2009-01-28
AU2007329807A1 (en) 2008-06-12
WO2008070305A3 (en) 2008-08-28
PT2099784E (pt) 2013-01-04
CL2007003002A1 (es) 2008-06-06
JP2010507590A (ja) 2010-03-11
TW200825067A (en) 2008-06-16
WO2008070306A2 (en) 2008-06-12
US7998985B2 (en) 2011-08-16
US8168659B2 (en) 2012-05-01
CA2667372C (en) 2013-09-03
KR20090069316A (ko) 2009-06-30

Similar Documents

Publication Publication Date Title
EP2094684B1 (en) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators
CN101454328A (zh) 新的mch受体拮抗剂
MXPA06006026A (es) Derivados de imidazol, procesos para prepararlos y sus usos.
AU2004285913A1 (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
JPH08225535A (ja) インダゾール誘導体
AU2009238444B2 (en) 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
AU2009238445B2 (en) 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
AU2007329807B2 (en) 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulator
WO1995010504A1 (en) 2-(1-alkoxy-2-naphthalenyl)-pyrrole derivatives, their preparation and their use as dopamine d3 receptor antagonists
TW200538435A (en) (2S)-2-[4-(2, 2-difluorovinyl)-2-oxopyrrolidin-1-yl]butanoic acids and their uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired